Understanding firm, physician and consumer choice behavior in the pharmaceutical industry

Marketing Letters

Volumn 16, Issue 3-4, 2005, Pages 293-308

  Manchanda, Puneet ^a   Wittink, Dick R ^b   Ching, Andrew ^c   Cleanthous, Paris ^d   Ding, Min ^e   Dong, Xiaojing J ^f   Leeflang, Peter S H ^g   Misra, Sanjog ^h   Mizik, Natalie ⁱ   Narayanan, Sridhar ^j   Steenburgh, Thomas ^k   Wieringa, Jaap E ^g   Wosinska, Marta ^k   Xie, Ying ^l  

^a UNIVERSITY OF CHICAGO   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d NEW YORK UNIVERSITY   (United States)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF GRONINGEN   (Netherlands)

^h UNIVERSITY OF ROCHESTER   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

^j STANFORD UNIVERSITY   (United States)

^k HARVARD UNIVERSITY   (United States)

^l RUTGERS UNIVERSITY   (United States)

more..

Author keywords

New products; Patient compliance; Pharmaceutical marketing; Pharmaceutical pricing; Physician networks; Response models

Indexed keywords

EID: 32044473496     PISSN: 09230645     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11002-005-5893-1     Document Type: Article

References (56)

1. Azoulay, Pierre. (2002). "Do Pharmaceutical Sales Respond to Scientific Evidence?" Journal of Economics and Management Strategy 11(4), 551-594.
2. Beavers, N. (1999). "Take as directed," Drug Topics 143(18), 56-65.
3. Berndt, Ernst R. (2002). "Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price," Journal, of Economic Perspectives 16(4), 45-66.
4. Bowman, D., C. M. Heilman, and P. B. Seetharaman. (2004). "Determinants of Product Use Compliance Behavior," Journal of Marketing Research 41 (August),
5. Burt, Ronald S. (1987). "Social Contagion and Innovation: Cohesion versus Structural Equivalence," American Journal of Sociology 92, 1287-1335.
6. Ching, Andrew. (2002). "Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs after Patent Expiration," Working Paper, University of Toronto.
7. Ching, Andrew. (2005). "The Effects of Detailing on Prescribing Decisions under Quality Uncertainty," Working Paper, University of Toronto.
8. Chintagunta, P. and Ramarao Desiraju. (2005). "Strategic Pricing and Detailing Behavior in International Markets," Marketing Science 24(1), 67-80.
9. Coscelli, Andrea and Matthew Shum. (2004). "An Empirical Model of Learning and Patient Spillovers in New Drug Entry," Journal of Econometrics 122, 213-246.
10. Cleanthous. (2002). "Patient Welfare Implications of Innovation and Diffusion in the U.S. Antidepressant Market," Working Paper, New York University.
11. Cleanthous. (2004). "Analyzing the Effects of Marketing Efforts by Pharmaceuticals on Patient Welfare," Working Paper, New York University.
12. Coleman, James S., Elihu Katz, and Herbert Menzel. (1966). Medical Innovation: A Diffusion Study. The Bobbs-Merill Company Inc.
13. Cramer, J. (2001). "The Usefulness of Medication Compliance Data in Interpretation of Outcomes," ISPOR News. (http://www.ispor.org/news/ articles/0705/compldata.htm).
14. Crawford, Gregory and Matthew Shum. (2005). "Uncertainty and Learning in Pharmaceutical Demand," Econometrica (forthcoming).
15. Desiraju, Ramarao, Harikesh Nair, and Pradeep K. Chintagunta. (2004). "Diffusion of New Pharmaceutical Drugs in Developing and Developed Nations," International Journal of Research in Marketing 21, 341-357.
16. Ding, M. and J. Eliashberg. (2002). "Structuring the New Product Development Pipeline, with J. Eliashberg," Management Science 48(3), 343-363.
17. Ding, Min and Jehoshua Eliashberg. (2004). "A Theory of Portfolio Optimization," Working Paper, Pennsylvania State University.
18. Dong, Xiaojing J., Puneet Manchanda and Pradeep K. Chintagunta. (2004). "Quantifying the Benefits of Individual Level Targeting in the Presence of Firm Strategic Behavior," Working Paper, Northwestern University.
19. Fraenkel, L. S. T. Bogardus, J. Concato, and D. R. Wittink. (2004). "Treatment Options in Knee Osteoarthritis: the Patient's Perspective," Archives of Internal Medicine (forthcoming).
20. Fincham, J. and A. Wertheimer. (1985). "Using the Health Belief Model to Predict Initial Drug Therapy Defaulting," Social Science and Medicine 20(1), 101-105.
21. Hahn, M., S. Park, L. Krishnamurthi, and A. A. Zoltners. (1994)." Analysis of New Product Diffusion Using a Four-Segment Trial-Repeat Model," Marketing Science 13 (3), 224-247.
22. Huffman, D. and R. Jackson. (1995). "The Financial Benefits of Improved Patient Compliance," NARD Journal 108-111.
23. Izuka, T. and G. Z. Jin. (2005). "The Effects of Prescription Drug Advertising on Doctor Visits," Journal of Economics and Management Strategy (forthcoming).
24. Jackson, R., D. Worthern, and C. McCampbell. (1996). "Economic Impact of Refill Management," US Pharmacist, 86-96.
25. Johnson, J. and L. Bootman. (1995). "Drug-Related Morbidity and Mortality: A Cost-of-Illness Model," Archives of Internal Medicine 155(18), 1949-1958.
26. Kanavos, P. and M. Gemmill. (2005). Pharmaceutical Pricing and Reimbursement in Europe. London, UK: PJB Publications.
27. Kolassa, E. M. (1997). Elements of Pharmaceutical Pricing. Binghamption, NY: The Pharmaceutical Products Press.
28. Leeflang, P., J. E. Wieringa, and D. R. Wittink. (2005). "Modeling the Effects of Promotion Expenditures on the Sales of Pharmaceuticals," Working Paper, University of Groningen.
29. Loch, C. H. and S. Kavadias. (2002). "Dynamic Portfolio Selection of NPD Programs Using Marginal Returns," Management Science 48(10), 1227-1241.
30. Loden, J. and C. Schooler. (2000). "Patient Compliance," Pharmaceutical Executive 20(7), 88-94.
31. Manchanda, Puneet, and Elisabeth Honka. (2005). "The Effects and Role of Direct-to-Physician Marketing in the Pharmaceutical Industry: An Integrative Review," Yale Journal of Health Policy, Law and Ethics 5(2), 785-822.
32. Manchanda, P. P. E. Rossi, and P. K. Chintagunta. (2004a). "Response Modeling with Non-Random Marketing Mix Variables," Journal of Marketing Research 41 (November), 467-478.
33. Manchanda, Puneet, Xiaojing J. Dong, and Pradeep K. Chintagunta. (2004b). "A Multicategory Model of Physician Prescription Behavior," Working Paper, University of Chicago.
34. Manchanda, Puneet, Ying Xie, and Nara Youn. (2004c). "The Role of Targeted Communication and Contagion in Product Adoption," Working Paper, University of Chicago.
35. Manchanda, Puneet, and Pradeep K. Chintagunta. (2004). "Responsiveness of Physician Prescription Behavior to Sales force Effort: An Individual Level Analysis," Marketing Letters 15(2-3), 129-145.
36. Misra, Sanjog. (2004). "Prescription Drug Choice: Preference, Persistence and Heterogeneity," Working Paper, Rochester University.
37. Mizik N. and R. Jacobson. (2004). "Are Physicians 'Easy Marks'? Quantifying the Effects of Detailing and Sampling on New Prescriptions," Management Science 50(12), 1704-1715.
38. Mukherjee, Prokriti. (2002). "A Structural Model of Learning for New Products," Working Paper, University of Minnesota.
39. Narayanan, Sridhar, and Puneet Manchanda. (2004). "Heterogeneous Learning and the Targeting of Marketing Communication for New Products," Working Paper, University of Chicago.
40. Narayanan, Sridhar, Ramarao Desiraju, and Pradeep K. Chintagunta. (2004). "ROI Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing Mix Interactions," Journal of Marketing 68(4), 90-105.
41. Narayanan, Sridhar, Puneet Manchanda, and Pradeep K. Chintagunta. (2005). "Temporal Differences in the Role of Marketing Communication in New Products Categories," Journal of Marketing Research 42(August), 278-290.
42. Neslin, Scott. (2001). "ROI Analysis of Pharmaceutical Promotion: An Independent Study," unpublished study conducted for the Association of Medical Publications, http:((www.rxpromoroi.org(rapp(index.html.
43. Rosenthal, M. B., E. R. Berndt, J. M. Donohue, A. Epstein, and R. G. Frank. (2003). Demand Effects of Recent Changes in Prescription Drug Promotion, Vol. 6 of Frontiers in Health Policy Research, MIT Press, 1-26.
44. Rosenthal, Meredith B., Ernst R. Berndt, Julie M. Donohue, Richard G. Frank, and Arnold M. Epstein. (2002). "Promotion of Prescription Drugs to Consumers," New England Journal of Medicine 346(7), 498-505.
45. Sabate, E. (2003). Adherence to Long-Term Therapies: Evidence for Action, World Health Organization, Geneva, Switzerland.
46. Stoneman P. (1981). "Intra-Firm Diffusion, Bayesian Learning and Profitability," Economic Journal 91(362), 375-88.
47. Strang, David and Nancy Brandon Tuma. (1993). "Spatial and Temporal Heterogeneity in Diffusion "American Journal of Sociology 99, 614-639.
48. Van den Bulte, C. and G. L. Lilien. (2001). "Medical Innovation Revisited: Social Contagion versus Marketing Effort," American Journal of Sociology 106(5), 1409-35.
49. Villas-Boas, M. and R. Winer. (1999). "Endogeneity in Brand Choice Models," Management Science 45, 1324-1338.
50. van der Pool, L. (2003). "Omnicom Expands in Health Category," AdWeek p. 12.
51. Wittink, R. Dick. (2002). "Analysis of ROI for Pharmaceutical Promotions," unpublished study conducted for the Association of Medical Publications, http://www.rxpromoroi.org/arpp/index.html.
52. Wosinska, M. (2002). "Just What the Patient Ordered: Direct-to-Consumer Advertising and Demand for Pharmaceutical Products," Working Paper, Harvard University.
53. Wosinska, M. (2005). "Direct-to-consumer advertising and drug therapy compliance," Journal of Marketing Research 42(August), 323-332.
54. Wosinska, M. and Robert S. Huckman. (2004). "Generic Dispensing and Substitution in Mail and Retail Pharmacies," Health Affairs 28, W4-409-W4-416.
55. Wosinska, M., D. Snow, K. Raube, and P. J. Gertler. (2004). "Effectiveness of Consumer Promotions in Adoption of Generic Drugs," Working Paper, Harvard University.
56. Xie, Ying. (2003). PhD dissertation: Essays on Promotion Mix Management: An Application to the Prescription Pharmaceutical Industry, Northwestern University, Evanston, Il.